Uromigos Live & Unplugged: Prostate Cancer Roundtable
The panel shares insights on future advancements in the field.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
The panel talks "pearls of wisdom" with radioligand therapy.
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.